ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the ...

The advent of ATTR-specific drugs, though pricey, is enabling better survival in these overlapping diseases, researchers say.

The drug is already approved in the EU for transthyretin amyloidosis with polyneuropathy but now covers patients with cardiomyopathy.

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

Heart failure often follows heart attacks, diabetes, or high blood pressure. However, a very different cause is being ...

– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. – ...

A new international study has found that treating both aortic valve narrowing and a lesser-known condition called cardiac ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The interim data, with a cutoff date of April 11, 2025, showed an impressive 70% CR rate. Prior to NXC-201 treatment, the ...

MSK cellular therapist Dr. Heather Landau led a phase 1 clinical trial showing CAR T cell therapy is effective against relapsed or resistant AL amyloidosis. “I’ve seen very sick patients have an ...